F Van Wanzeele
Overview
Explore the profile of F Van Wanzeele including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
71
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Degroote S, Vogelaers D, Vermeir P, Mariman A, De Rick A, Van Der Gucht B, et al.
Acta Clin Belg
. 2014 Apr;
69(2):111-5.
PMID: 24724750
Since the era of highly active antiretroviral therapy (HAART), HIV is considered a chronic disease. Adherence to HAART is crucial for effectiveness. Non-adherence negatively impacts patient outcome and the larger...
2.
Ricciardi S, Van Wanzeele F, Troisi R
Acta Chir Belg
. 2007 May;
107(2):215-8.
PMID: 17515275
We report the case of a 54-year old man with decompensated alcoholic liver cirrhosis and HIV infection who underwent liver transplantation (LT). Due to relatively well preserved cellular immunity until...
3.
Moerman M, Danielides V, Nousia C, Van Wanzeele F, Forsyth R, Vermeersch H
Dermatology
. 2001 Dec;
203(4):339-41.
PMID: 11752826
There are few reports on focal epithelial hyperplasia (FEH) in association with human immunodeficiency virus (HIV) infection; thus the relationship between them has not been completely clarified yet. We present...
4.
Van Vaerenbergh K, Van Laethem K, Van Wijngaerden E, Schmit J, Schneider F, Ruiz L, et al.
AIDS Res Hum Retroviruses
. 2000 Apr;
16(6):529-37.
PMID: 10777143
We evaluated the predictive value of baseline HIV-1 genotypic resistance mutations for failure of a nucleoside reverse transcriptase inhibitor (NRTI) containing therapy. The change in therapy of 88 HIV-1-infected patients...
5.
Gisolf E, Jurriaans S, Pelgrom J, Van Wanzeele F, van der Ende M, Brinkman K, et al.
AIDS
. 2000 Apr;
14(4):405-13.
PMID: 10770543
Objective: To evaluate the effect of treatment with ritonavir (RTV)/saquinavir (SQV)/6 stavudine (D4T) or RTV/SQV alone, with treatment intensification if needed, in protease inhibitor- and D4T-naïve HIV-1-infected individuals. Design: Multicentre,...
6.
Colebunders R, Clumeck N, Florence E, Vandercam B, Van Wanzeele F, Van Wijngaerden E, et al.
Acta Clin Belg
. 1999 Jul;
54(2):55-60.
PMID: 10394641
No abstract available.
7.
Delanghe J, Langlois M, Boelaert J, Van Acker J, Van Wanzeele F, van der Groen G, et al.
AIDS
. 1998 Jul;
12(9):1027-32.
PMID: 9662199
Background: Three phenotypes of the antioxidant protein haptoglobin are known: Hp 1-1, Hp 2-1 and Hp 2-2. Objectives: To investigate the outcome of HIV infection according to haptoglobin type. Design...
8.
Staszewski S, Miller V, Kober A, Colebunders R, Vandercam B, Delescluse J, et al.
Antivir Ther
. 1996 Jan;
1(1):42-50.
PMID: 11322258
No abstract available.
9.
Verhofstede C, Reniers S, Van Wanzeele F, Plum J
AIDS
. 1994 Oct;
8(10):1421-7.
PMID: 7529507
Objective: We compared the proviral DNA level in peripheral blood mononuclear cells (PBMC), viral RNA level in plasma, presence of p24 antigen in serum, viral phenotype, and results of immunological...
10.
Verhofstede C, Reniers S, Colebunders R, Van Wanzeele F, Plum J
AIDS
. 1993 Nov;
7(11):1539-41.
PMID: 8280431
No abstract available.